Ryu Hyo Seon, Kim Hyun Jung, Ji Woong Bae, Kim Byung Chang, Kim Ji Hun, Moon Sung Kyung, Kang Sung Il, Kwak Han Deok, Kim Eun Sun, Kim Chang Hyun, Kim Tae Hyung, Noh Gyoung Tae, Park Byung-Soo, Park Hyeung-Min, Bae Jeong Mo, Bae Jung Hoon, Seo Ni Eun, Song Chang Hoon, Ahn Mi Sun, Eo Jae Seon, Yoon Young Chul, Yoon Joon-Kee, Lee Kyung Ha, Lee Kyung Hee, Lee Kil-Yong, Lee Myung Su, Lee Sung Hak, Lee Jong Min, Lee Ji Eun, Lee Han Hee, Ihn Myong Hoon, Jang Je-Ho, Jeon Sun Kyung, Chae Kum Ju, Choi Jin-Ho, Pyo Dae Hee, Ha Gi Won, Han Kyung Su, Hong Young Ki, Hong Chang Won, Kwak Jung-Myun
Division of Colon and Rectal Surgery, Department of Surgery, Korea University College of Medicine, Seoul, Korea.
Department of Preventive Medicine, Korea University College of Medicine, Seoul, Korea.
Ann Coloproctol. 2024 Apr;40(2):89-113. doi: 10.3393/ac.2024.00059.0008. Epub 2024 Apr 30.
Colorectal cancer is the third most common cancer in Korea and the third leading cause of death from cancer. Treatment outcomes for colon cancer are steadily improving due to national health screening programs with advances in diagnostic methods, surgical techniques, and therapeutic agents.. The Korea Colon Cancer Multidisciplinary (KCCM) Committee intends to provide professionals who treat colon cancer with the most up-to-date, evidence-based practice guidelines to improve outcomes and help them make decisions that reflect their patients' values and preferences. These guidelines have been established by consensus reached by the KCCM Guideline Committee based on a systematic literature review and evidence synthesis and by considering the national health insurance system in real clinical practice settings. Each recommendation is presented with a recommendation strength and level of evidence based on the consensus of the committee.
在韩国,结直肠癌是第三大常见癌症,也是癌症死亡的第三大主要原因。由于国家健康筛查计划,以及诊断方法、手术技术和治疗药物的进步,结肠癌的治疗效果正在稳步改善。韩国结肠癌多学科(KCCM)委员会旨在为治疗结肠癌的专业人员提供最新的、基于证据的实践指南,以改善治疗效果,并帮助他们做出反映患者价值观和偏好的决策。这些指南是由KCCM指南委员会在系统的文献综述和证据综合的基础上,并考虑实际临床实践中的国家医疗保险系统,通过达成共识而制定的。每项建议都根据委员会的共识给出了推荐强度和证据水平。
Ann Coloproctol. 2024-4
Early Hum Dev. 2020-11